The Impact of Fact Issues on Patent Eligibility after Berkheimer | IP Litigator Issue May/June 2019

Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....

In their recent Inventors Digest article, Knobbe Martens lawyers Alistair McIntyre and Tom Cowan examine key developments in Section 101 patent eligibility, and offer practical guidance for inventors navigating complex...

VLSI TECHNOLOGY LLC v. INTEL CORP. Before Moore, Chen, and Kleeh.  Appeal from the United States District Court for the Northern District of California. Summary: The Federal Circuit reversed summary...